Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track

06/01

Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.

The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).

Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1128280885"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128280885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128280885?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128280885","market":"sg","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-01 15:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1128280885","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128280885","pubTimestamp":1780299350,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"股票追踪|Summit Therapeutics因Ivonescimab肺癌试验结果积极飙升11.46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}